Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Value Fund median (23 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 05 Mar 2025 – 20 Aug 2026, limited by Mahindra Manulife Value Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Mahindra Manulife Value Fund | Nifty 500 |
|---|---|---|
| 05 Mar 2025 | ₹100.00 | ₹100.00 |
| 18 Apr 2025 | ₹104.90 | ₹107.04 |
| 02 Jun 2025 | ₹110.98 | ₹112.73 |
| 16 Jul 2025 | ₹115.67 | ₹115.88 |
| 30 Aug 2025 | ₹108.69 | ₹110.89 |
| 13 Oct 2025 | ₹113.24 | ₹115.00 |
| 27 Nov 2025 | ₹117.85 | ₹118.22 |
| 10 Jan 2026 | ₹118.05 | ₹115.85 |
| 23 Feb 2026 | ₹119.42 | ₹115.94 |
| 09 Apr 2026 | ₹114.92 | ₹108.79 |
| 23 May 2026 | ₹119.69 | ₹111.82 |
| 07 Jul 2026 | ₹124.45 | ₹115.36 |
| 20 Aug 2026 | ₹126.25 | ₹116.08 |
| Metric | Mahindra Manulife · Regular NAV ₹12.73 Very High risk ★★★★☆ 1Y | Category median Value Fund · 23 funds |
|---|---|---|
| +12.46% | +2.35% | |
| — | +13.86% | |
| — | +13.50% | |
| — | +13.29% | |
| +17.32% | +14.30% | |
| +13.38% | — | |
| — | +16.80% | |
| — | +14.35% | |
| — | +14.21% | |
| Risk | ||
| 14.68% | 14.36% | |
| 0.41 | 0.51 | |
| 0.57 | 0.69 | |
| -11.69% | -40.31% | |
| Nifty 500 | — | |
| — | +1.91% | |
| — | 0.96 | |
| — | 101.5% | |
| — | 95.5% | |
| 2.54% | 2.28% | |
| ₹803.99Cr | ₹1,662Cr | |
| Up to 0.50% | — | |
| None | — | |
| ₹500 | — | |
| ₹1.00K | — | |
| — | 36% | |
| Krishna Sanghavi · 1.5y | — | |
| 05 Mar 2025 | — | |
| 72 | — | |
| 26.6% | — | |
| 4.3% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.